LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

17.36 -1.08

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.15

Max

17.61

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.8M

-4.1M

Verkoop

8.3M

108M

K/W

Sectorgemiddelde

14.645

57.833

EPS

0.12

Winstmarge

-3.79

Werknemers

761

EBITDA

-5.7M

1.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+42.05% upside

Dividenden

By Dow Jones

Volgende Winsten

29 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-109M

891M

Vorige openingsprijs

18.44

Vorige sluitingsprijs

17.36

Nieuwssentiment

By Acuity

81%

19%

327 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mrt 2026, 22:51 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mrt 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mrt 2026, 20:31 UTC

Winsten

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mrt 2026, 23:49 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mrt 2026, 23:31 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery -- Market Talk

18 mrt 2026, 22:49 UTC

Marktinformatie

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mrt 2026, 22:41 UTC

Marktinformatie

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mrt 2026, 22:36 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mrt 2026, 22:24 UTC

Winsten

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mrt 2026, 21:58 UTC

Winsten

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mrt 2026, 21:55 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

18 mrt 2026, 21:55 UTC

Marktinformatie
Winsten

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mrt 2026, 21:40 UTC

Marktinformatie

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mrt 2026, 21:16 UTC

Marktinformatie

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mrt 2026, 21:00 UTC

Belangrijke Nieuwsgebeurtenissen

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mrt 2026, 20:58 UTC

Winsten

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mrt 2026, 20:41 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:29 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:25 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:17 UTC

Winsten

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mrt 2026, 20:14 UTC

Marktinformatie

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mrt 2026, 20:09 UTC

Winsten

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mrt 2026, 20:07 UTC

Winsten

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mrt 2026, 20:06 UTC

Winsten

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mrt 2026, 20:03 UTC

Winsten

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

42.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  42.05%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

327 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat